查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813816

美國細胞治療材料市場：市場規模、佔有率、趨勢分析（按產品、最終用途和地區）、細分市場預測（2025-2033）

U.S. Cell Therapy Raw Materials Market Size, Share & Trends Analysis Report By Product (Media, Sera, Antibodies, Reagents & Buffers), By End-use (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

美國細胞治療原料市場規模預計在 2024 年達到 20.6 億美元，預計到 2033 年將達到 93.7 億美元，2025 年至 2033 年的複合年成長率為 18.42%。

成長的驅動力來自於細胞療法核准數量的增加、對GMP級高品質投入的需求不斷成長以及再生醫學的進步。此外，生物製造能力的提升、資金籌措的增加以及CDMO在治療方法開發中日益增強的作用，也進一步推動了市場的發展，因為該行業優先考慮可靠、擴充性且合規的原料，以支持臨床和商業性的細胞療法項目。

不斷擴大的治療管道推動了組件需求

受個人化療法興起及其製造過程日益複雜化的推動，美國細胞和基因治療材料產業正經歷強勁成長。隨著細胞療法從研究階段走向商業化，對培養基、質體DNA、生長因子和病毒載體等高高等級原料的需求正在飆升。開發商正在尋求具有一致性、擴充性和合規性的產品，以支持臨床和商業規模的生產。此外，原料供應商加強投資、擴建設施和技術升級，進一步推動了市場發展，並增強了支持先進療法開發的基礎設施。

這種需求體現在不斷擴大的細胞和基因治療候選藥物研發管線中，這些候選藥物正在臨床試驗中取得進展。如附表所示，Anitocel（Arcellx/吉利德）和OTL 203（Orchard Therapeutics）等療法正處於II期和III期臨床試驗階段，針對多發性骨髓瘤和Hurler症候群等複雜疾病。這些臨床試驗以及其他處於早期和中期研發階段的療法，展現了正在探索的適應症和技術的多樣性。

這些治療方法的開發在很大程度上依賴可重複且合規的生產所需的專用原料。因此，療法開發商與原料供應商之間的策略夥伴關係關係日益普遍，凸顯了原料在支持創新和推動美國細胞療法長期成長方面發揮的關鍵作用。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章市場因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析

第4章 產品業務分析

  • 細分儀表板：依產品
  • 美國細胞治療原料市場：產品差異分析（按產品）
  • 美國細胞治療原料市場規模及趨勢分析（依產品）（2021-2033）
  • 培養基
    • 文化媒體市場（2021-2033）
  • 電漿
    • 等離子市場（2021-2033）
  • 細胞培養補充劑
    • 細胞培養補充劑市場（2021-2033）
  • 抗體
    • 抗體市場（2021-2033）
  • 試劑和緩衝溶液
    • 試劑和緩衝液市場（2021-2033）
  • 其他
    • 其他市場（2021-2033）

第5章 按最終用途分類的業務分析

  • 細分儀表板：依最終用途
  • 美國細胞治療材料市場：按最終用途分類的產品差異分析
  • 美國細胞治療原料市場規模及趨勢分析（依最終用途）（2021-2033）
  • 生物製藥和製藥公司
    • 生物製藥和醫藥市場（2021-2033）
  • 合約風險評估/合約行銷
    • CRO/CMO市場（2021-2033）
  • 其他
    • 其他市場（2021-2033）

第6章 競爭態勢

  • 公司分類
  • 戰略地圖
  • 公司地位分析（2024年）
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Actylis.
    • ACROBiosystems
    • STEMCELL Technologies
    • Grifols, SA
    • Charles River Laboratories
    • RoosterBio, Inc.
    • PromoCell GmbH
    • Danaher
    • Sartorius Stedim Biotech
Product Code: GVR-4-68040-698-7

Market Size & Trends:

The U.S. cell therapy raw materials market size was estimated at USD 2.06 billion in 2024 and is projected to reach USD 9.37 billion by 2033, growing at a CAGR of 18.42% from 2025 to 2033. Growth is driven by the rising number of cell therapy approvals, increasing demand for GMP-grade and high-quality inputs, and advancements in regenerative medicine. In addition, expanding biomanufacturing capabilities, increased funding, and the growing role of CDMOs in therapeutic development are further propelling the market forward, as the industry prioritizes reliable, scalable, and regulatory-compliant raw materials to support clinical and commercial cell therapy programs.

Expanding Therapy Pipelines Drive Demand for Components

The U.S. cell and gene therapy raw materials industry is experiencing strong growth, driven by the increasing number of personalized therapies and the complexity of their manufacturing processes. As cell therapies transition from research to commercialization, demand for high-grade raw materials-such as culture media, plasmid DNA, growth factors, and viral vectors-has surged. Developers seek products that offer consistency, scalability, and regulatory compliance to support both clinical and commercial-scale production. Moreover, rising investments, facility expansions, and technology upgrades by raw material suppliers have further accelerated market momentum, strengthening the infrastructure supporting advanced therapy development.

This demand is reflected in the expanding pipeline of cell and gene therapy candidates progressing through clinical trials. As seen in the accompanying table, therapies like Anito cel (Arcellx/Gilead) and OTL 203 (Orchard Therapeutics) are advancing through Phase II and III stages, targeting complex conditions such as multiple myeloma and Hurler syndrome. These trials, along with others in early and mid-development phases, illustrate the diversity of indications and technologies being pursued.

The development of such therapies relies heavily on specialized raw materials for reproducible and compliant manufacturing. As a result, strategic partnerships between therapy developers and raw material providers are becoming increasingly common, highlighting the foundational role of raw materials in supporting innovation and driving long-term growth across the U.S. cell therapy landscape.

U.S. Cell Therapy Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. cell therapy raw materials market report based on the product, and end use:

  • Product Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Media
  • Sera
  • Cell Culture Supplements
  • Antibodies
  • Reagents & Buffers
  • Others
  • End Use Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. End Use Segment
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising demand for cell therapies
      • 3.2.1.2. Advancements in research and development for cell-based therapies
      • 3.2.1.3. Technological Innovation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with the production and procurement of raw materials
      • 3.2.2.2. Stringent regulations associated with cell therapies
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Cell Therapy Raw Materials Market: Product Movement Analysis
  • 4.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
  • 4.4. Media
    • 4.4.1. Media Market, 2021 - 2033 (USD Million)
  • 4.5. Sera
    • 4.5.1. Sera Market, 2021 - 2033 (USD Million)
  • 4.6. Cell Culture Supplements
    • 4.6.1. Cell Culture Supplements Market, 2021 - 2033 (USD Million)
  • 4.7. Antibodies
    • 4.7.1. Antibodies Market, 2021 - 2033 (USD Million)
  • 4.8. Reagents & Buffers
    • 4.8.1. Reagents & Buffers Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. U.S. Cell Therapy Raw Materials Market: End Use Movement Analysis
  • 5.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
  • 5.4. Biopharmaceutical & Pharmaceutical Companies
    • 5.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
  • 5.5. CROs & CMOs
    • 5.5.1. CROs & CMOs Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Position Analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. Thermo Fisher Scientific Inc.
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Merck KGaA
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Actylis.
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. ACROBiosystems
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. STEMCELL Technologies
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Grifols, S.A.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Charles River Laboratories
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives
    • 6.4.8. RoosterBio, Inc.
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Strategic Initiatives
    • 6.4.9. PromoCell GmbH
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Strategic Initiatives
    • 6.4.10. Danaher
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Strategic Initiatives
    • 6.4.11. Sartorius Stedim Biotech
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Strategic Initiatives

List of Tables

  • Table 1. U.S. cell therapy raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 2. U.S. cell therapy raw materials market, by end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 U.S. cell therapy raw materials market segmentation
  • Fig. 3 Data analysis models
  • Fig. 4 Market formulation and validation
  • Fig. 5 Data validating & publishing
  • Fig. 6 Market research process
  • Fig. 7 Information procurement
  • Fig. 8 Primary research
  • Fig. 9 Market formulation & validation
  • Fig. 10 Commodity flow analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 Porter's five force analysis
  • Fig. 17 SWOT analysis, by factor (Political, Economic, Social, Technological, and Legal)
  • Fig. 18 U.S. cell therapy raw materials market: Product outlook key takeaways
  • Fig. 19 U.S. cell therapy raw materials market: Product movement analysis
  • Fig. 20 Media market, 2021 - 2033 (USD Million)
  • Fig. 21 Sera market, 2021 - 2033 (USD Million)
  • Fig. 22 Cell culture supplements market, 2021 - 2033 (USD Million)
  • Fig. 23 Antibodies market, 2021 - 2033 (USD Million)
  • Fig. 24 Reagents & buffers market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. cell therapy raw materials market: End-use outlook key takeaways
  • Fig. 27 U.S. cell therapy raw materials market: End-use movement analysis
  • Fig. 28 Biopharmaceutical & pharmaceutical companies market, 2021 - 2033 (USD Million)
  • Fig. 29 CROs & CMOs supplements market, 2021 - 2033 (USD Million)
  • Fig. 30 Others supplements market, 2021 - 2033 (USD Million)